Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumazenil for Reversal of Remimazolam Sedation in Hip Arthroplasty
NCT07277881Phase 4Not yet recruiting
- Sponsor
- Medical University of Gdańsk
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Allosteric Modulators
01
Overview
Phase 4, randomised, double-blind trial in postoperative delirium (POD) and Postoperative neurocognitive disorder (PND) comparing Flumazenil Group with Placebo Group (2 arms). Primary endpoint: Change in Montreal Cognitive Assessment score at 24 hours. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
flumazenil
03
Conditions
postoperative delirium (POD)Postoperative neurocognitive disorder (PND)
Beyond the preview
Go deeper on NCT07277881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277881.